JLE

Hépato-Gastro & Oncologie Digestive

MENU

Contribution of fecal calprotectin in monitoring the inflammatory bowel diseases Volume 22, issue 6, Juin 2015

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

Tables

Authors
1 Centre Hospitalier Lyon-Sud,
Hospices Civils de Lyon,
Service d’Hépato-Gastroentérologie,
69495 Pierre-Bénite, France
2 Centre Hospitalier Lyon-Sud,
Hospices Civils de Lyon,
69495 Pierre-Bénite, France
3 INSERM U1111 « Immunité des muqueuses-Vaccination-Biothérapies »,
Centre International de Recherche en Infectiologie (CIRI),
21 avenue Tony Garnier,
69007 Lyon Cedex, France
* Tirés à part

The therapeutic strategies in the management of patients with inflammatory bowel diseases (IBD) have changed these last years and have to take into account objective parameters of disease activity and mucosal healing beyond symptoms including various tools such as endoscopy, cross-sectional imaging and biomarkers with the aim to help making decision. Whereas CRP is the most widely used marker of inflammation in the monitoring of IBD, the dosages in the stools of markers reflecting intestinal inflammation are promising and have been widely developed in the field of IBD. Among these laboratory markers, calprotectin has been extensively investigated and is considered up to day as the most accurate marker for monitoring IBD. As soon its measurement will be reimbursed, its use in daily practice should rapidly develop. This review aimed to determine the usefulness of fecal calprotectin in the management of patients with Crohn's disease and ulcerative colitis by focusing especially on the optimal thresholds of its concentration that are distinct according to the objective of the dosage as well as its limits of interpretation.